Pharmacological Evaluation of New 4, 5-dihydro-1H- Pyrazole-1-yl acetate Derivatives as anti-cancer agents

Authors

  • Shahlaa Zuhair Abdul-Majeed Department of Pharmaceutical Chemistry, College of pharmacy, Mustansiriyah University, Baghdad, Iraq
  • Monther Faisal Mahdi Department of Pharmaceutical Chemistry, College of pharmacy, Mustansiriyah University, Baghdad, Iraq
  • Suhad Faisal Hatem Al-Mugdadi Department of Clinical Laboratory science, College of pharmacy, Mustansiriyah University, Baghdad, Iraq

DOI:

https://doi.org/10.32947/ajps.v22i4.963

Keywords:

Pyrazole, anticancer, 4, 5-dihydro-1H- Pyrazole, MCF-7, A549

Abstract

A series of nine novel 4, 5-dihydro-1H- pyrazole-1-yl acetate derivatives (IVa-i) by Shahlaa et al. was investigated in vitro for their antiproliferative activity against two cancer cell lines, breast cancer cell line (MCF-7) and lung cancer cell lines (A549), According to

 

the cytotoxicity effect of these compounds, IVa, IVc and IVi compounds have antiproliferative effect with percentage (81.30%, 87.4% & 54.66%) respectively at 72h treatment on MCF-7 cell line compared to other compounds, these results indicate that the new compound IVc have the higher antiproliferative percent comparable to tamoxifen as a standard anti-tumour for oestrogen receptor positive breast cancer cell line after 72h followed by IVa after 72h (83.31%). cytotoxicity effect of compound IVb was highest among tested compounds on lung cancer cell line (A549) with antiproliferative percentage (58.49% & 75.04%) at 48 & 72h respectively, but it is less than erlotinib as a standard anti-tumour for lung cancer cell line cytotoxicity effect (77.10% & 82.46%) at these times. three compounds (IVa, IVc & IVi) have antiproliferative effect on breast cancerous cell line (MCF-7) and compound (IVc) have inhibition percentage comparable to that of the authorized medication Tamoxifen. One compound (IVb) had antiproliferative activity, but less than that of erlotinib on lung cancerous cell line (A549) and there is good agreement between our docking results and the experimental results.

References

- Sinha T. Tumors: benign and malignant. Cancer Therapy & Oncology International Journal. 2018.10(3):52-4. DOI: https://doi.org/10.19080/CTOIJ.2018.10.555790

- Ritter JM, Rang HP, Flower RJ, Henderson G. Rang & Dale's Pharmacology E-Book: with STUDENT CONSULT Online Access: Elsevier Health Sciences.2014.

- Sharma D, Kumar S, Narasimhan B. Estrogen alpha receptor antagonists for the treatment of breast cancer: a review. Chemistry Central Journal. 2018.12(1):1-32. DOI: https://doi.org/10.1186/s13065-018-0472-8

- Murugesan S, Murugesan J, Palaniappan S, Palaniappan S, Murugan T, Siddiqui SS, et al. Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. Current Cancer Drug Targets. 2021.21(1):55-69. DOI: https://doi.org/10.2174/1568009620666201009130008

- Amala B., Sneha A., Femy M., Dr.Vinod B. A Scrupulous Review on Multifaceted Pyrazole Nucleus as an Energetic Pharmacological Agent. International Journal of Pharmaceutical Sciences Review and Research. 2021;69(2): 245-55. DOI: https://doi.org/10.47583/ijpsrr.2021.v69i02.036

- Abdul-Majeed SZ, Mahdi MF, Al-Mugdadi SFH. Design, Molecular Docking Studies, Synthesis and Characterization of some New 4, 5-dihydro-1H-Pyrazole-1-yl acetate Derivatives as Cyclooxygenase Inhibitors. Research Journal of Pharmacy and Technology. 2022.15(8):3382-90. DOI: https://doi.org/10.52711/0974-360X.2022.00566

- Ananda H, Kumar KSS, Sudhanva MS, Rangappa S, Rangappa KS. A trisubstituted pyrazole derivative reduces DMBA-induced mammary tumor growth in rats by inhibiting estrogen receptor-α expression. Molecular and cellular biochemistry. 2018.449(1):137-44. DOI: https://doi.org/10.1007/s11010-018-3350-8

- Sun R, Song J, Liu SJ, Zhao H, Yan CL, Zhang AJ, et al. Design, synthesis and biological evaluation of 1, 4-dihydrothieno [3′, 2′: 5, 6] thiopyrano [4, 3-c] pyrazole-3-carboxylic amide derivatives as potential estrogen receptor antagonists. Chinese Chemical Letters. 2011. 22(3):256-9. DOI: https://doi.org/10.1016/j.cclet.2010.10.029

- Lv P-C, Li H-Q, Sun J, Zhou Y, Zhu H-L. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. Bioorganic & medicinal chemistry. 2010.18 (13):4606-14. DOI: https://doi.org/10.1016/j.bmc.2010.05.034

- Xu Y, Liu X-H, Saunders M, Pearce S, Foulks JM, Parnell KM, et al. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). Bioorganic & medicinal chemistry letters. 2014.24(2):515-9. DOI: https://doi.org/10.1016/j.bmcl.2013.12.028

- Zheng L-W, Shao J-H, Zhao B-X, Miao J-Y. Synthesis of novel pyrazolo [1, 5-a] pyrazin-4 (5H)-one derivatives and their inhibition against growth of A549 and H322 lung cancer cells. Bioorganic & medicinal chemistry letters. 2011.21(13):3909-13. DOI: https://doi.org/10.1016/j.bmcl.2011.05.035

- Liu Y-R, Luo J-Z, Duan P-P, Shao J, Zhao B-X, Miao J-Y. Synthesis of pyrazole peptidomimetics and their inhibition against A549 lung cancer cells. Bioorganic & medicinal chemistry letters. 2012.22(22):6882-7. DOI: https://doi.org/10.1016/j.bmcl.2012.09.032

- Hussein AN, Abdul-Rasheed OF, Mahdi MF, Raauf AM. The Evaluation of Antiproliferative Effect of Imatinib derivatives Against Breast and Colon Cell-Lines. International Journal of Pharmaceutical Quality Assurance. 2020. 11:74-82. DOI: https://doi.org/10.25258/ijpqa.11.1.22

- Marin V, Kaplanski G, Gres S, Farnarier C, Bongrand P. Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells. Journal of immunological methods. 2001.254(1-2):183-90. DOI: https://doi.org/10.1016/S0022-1759(01)00408-2

- Qusay A, Marie NK, Al-Sudani BT. Utilization of natural stabilizer to prepare liposomal conjugate for the newly developed aptamer. Systematic Reviews in Pharmacy. 2020.11(7):32-50.

- Basma Talib Al-Sudani1, NHM, FHA-S. Redounding of Cuscuta chinensis Lam. on BxPC-3, HepG2, and U2OS Human Cancer Cell Lines. International Journal of Drug Delivery Technology. 2020.10 (3):354-9. DOI: https://doi.org/10.25258/ijddt.10.3.8

- Alawad KM, Mahdi MF, Raauf AM. Molecular Docking study, and In vitro Evaluation of Antitumor Activity of Some New Isoxazoline and Pyrazoline Derivatives of Nabumetone against breast cancer cell line (MCF-7). Al Mustansiriyah Journal of Pharmaceutical Sciences. 2022 Oct 24.22(3):24-34. DOI: https://doi.org/10.32947/ajps.v22i3.886

- Bedewi BK, Jasim GA, Abbas IS, Al-Sudani B. Cytotoxicity of Cryptochlorogenic acid against Breast cancer cell line (MCF7) isolated from Moringa oleifera Leaves Cultivated in Iraq. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2022 Jul 5.22(2):35-43. DOI: https://doi.org/10.32947/ajps.v22i2.837

Downloads

Published

2023-01-15

How to Cite

Shahlaa Zuhair Abdul-Majeed, Monther Faisal Mahdi, & Suhad Faisal Hatem Al-Mugdadi. (2023). Pharmacological Evaluation of New 4, 5-dihydro-1H- Pyrazole-1-yl acetate Derivatives as anti-cancer agents. Al Mustansiriyah Journal of Pharmaceutical Sciences, 22(4), 80–89. https://doi.org/10.32947/ajps.v22i4.963

Issue

Vol. 22 No. 4 (2022): (Volume22,Issue4,Year2022)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

AJPS is an open-access journal that all contents are free of charge. Articles of this journal are licensed under the terms of the Creative Commons Attribution International Public License CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/legalcode) that licensees are unrestrictly allowed to search, download, share, distribute, print, or link to the full texts of the articles, crawl them for indexing and reproduce any medium of the articles provided that they give the author(s) proper credits (citation). The journal allows the author(s) to retain the copyright of their published article.
Creative Commons-Attribution (BY) 
Crossref
Scopus
Google Scholar
Europe PMC